{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:13:55Z","timestamp":1794600835475,"version":"4.9.1"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/cji.0b013e3181ac6138","type":"journal-article","created":{"date-parts":[[2009,7,17]],"date-time":"2009-07-17T07:24:09Z","timestamp":1247815449000},"page":"689-702","source":"Crossref","is-referenced-by-count":372,"title":["Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor"],"prefix":"10.1097","volume":"32","author":[{"given":"James N.","family":"Kochenderfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20210227","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428190701851364","article-title":"Therapeutic options in mantle cell lymphoma","volume":"49","author":"Gill","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R3-2-20210227","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.seminoncol.2006.01.014","article-title":"Initial therapy for patients with chronic lymphocytic leukemia","volume":"33","author":"Wierda","year":"2006","journal-title":"Semin Oncol"},{"key":"R4-2-20210227","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"R5-2-20210227","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"R6-2-20210227","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2\u2009Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"R7-2-20210227","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2006.01.001","article-title":"The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma","volume":"20","author":"Van","year":"2006","journal-title":"Blood Rev"},{"key":"R8-2-20210227","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bmt.1704290","article-title":"Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation","volume":"32","author":"Mandigers","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R9-2-20210227","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1182\/blood-2002-02-0506","article-title":"The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"100","author":"Marks","year":"2002","journal-title":"Blood"},{"key":"R10-2-20210227","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705074","article-title":"Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation","volume":"36","author":"Russell","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R11-2-20210227","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"R12-2-20210227","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"R13-2-20210227","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/ni1001-957","article-title":"Immunotherapy through TCR gene transfer [see comment]","volume":"2","author":"Kessels","year":"2001","journal-title":"Nature Immunol"},{"key":"R14-2-20210227","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/hum.2005.16.457","article-title":"Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions","volume":"16","author":"Hughes","year":"2005","journal-title":"Human Gene Ther"},{"key":"R15-2-20210227","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes [see comment]","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"R16-2-20210227","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"R17-2-20210227","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0092-8674(89)90943-4","article-title":"Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice","volume":"58","author":"Becker","year":"1989","journal-title":"Cell"},{"key":"R18-2-20210227","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nature Rev Cancer"},{"key":"R19-2-20210227","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"R20-2-20210227","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.178.1.361","article-title":"Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain","volume":"178","author":"Hwu","year":"1993","journal-title":"J Exp Med"},{"key":"R21-2-20210227","first-page":"3369","article-title":"In vivo antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes","volume":"55","author":"Hwu","year":"1995","journal-title":"Cancer Res"},{"key":"R22-2-20210227","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2002-04-1041","article-title":"Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. [erratum appears in Blood. 2003 May 15;101:3808]","volume":"100","author":"Haynes","year":"2002","journal-title":"Blood"},{"key":"R23-2-20210227","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R24-2-20210227","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4049\/jimmunol.166.1.182","article-title":"Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta versus Fc epsilon RI-gamma","volume":"166","author":"Haynes","year":"2001","journal-title":"J Immunol"},{"key":"R25-2-20210227","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"R26-2-20210227","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R27-2-20210227","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"R28-2-20210227","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.162.9.5037","article-title":"Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal","volume":"162","author":"Takahashi","year":"1999","journal-title":"J Immunol"},{"key":"R29-2-20210227","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses","volume":"186","author":"Shuford","year":"1997","journal-title":"J Exp Med"},{"key":"R30-2-20210227","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"R31-2-20210227","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/hum.2007.028","article-title":"Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains","volume":"18","author":"Wang","year":"2007","journal-title":"Human Gene Ther"},{"key":"R32-2-20210227","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","article-title":"B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes","volume":"131","author":"Nadler","year":"1983","journal-title":"J Immunol"},{"key":"R33-2-20210227","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"R34-2-20210227","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","article-title":"Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins","volume":"71","author":"Uckun","year":"1988","journal-title":"Blood"},{"key":"R35-2-20210227","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V82.2.417.417","article-title":"Characterization and functional analysis of adult human bone marrow cell subsets in relation to B-lymphoid development","volume":"82","author":"Pontvert-Delucq","year":"1993","journal-title":"Blood"},{"key":"R36-2-20210227","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R37-2-20210227","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.22666","article-title":"Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials","volume":"109","author":"Rafailidis","year":"2007","journal-title":"Cancer"},{"key":"R38-2-20210227","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10875-007-9075-1","article-title":"Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency","volume":"27","author":"Quinti","year":"2007","journal-title":"J Clin Immunol"},{"key":"R39-2-20210227","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","article-title":"Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma","volume":"34","author":"Nicholson","year":"1997","journal-title":"Mol Immunol"},{"key":"R40-2-20210227","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2002-07-1989","article-title":"T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect","volume":"101","author":"Cooper","year":"2003","journal-title":"Blood"},{"key":"R41-2-20210227","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nature Biotechnol"},{"key":"R42-2-20210227","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0378-1119(89)90358-2","article-title":"Site-directed mutagenesis by overlap extension using the polymerase chain reaction","volume":"77","author":"Ho","year":"1989","journal-title":"Gene"},{"key":"R43-2-20210227","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1073\/pnas.80.20.6351","article-title":"Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells","volume":"80","author":"Ochi","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R44-2-20210227","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1073\/pnas.90.17.8033","article-title":"Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. [see comment]","volume":"90","author":"Burns","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"R45-2-20210227","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1089\/hum.1996.7.8-913","article-title":"Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors","volume":"7","author":"Porter","year":"1996","journal-title":"Human Gene Ther"},{"key":"R46-2-20210227","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1089\/hum.1997.8.10-1189","article-title":"A simple and reliable method for screening retroviral producer clones without selectable markers","volume":"8","author":"Onodera","year":"1997","journal-title":"Human Gene Ther"},{"key":"R51-2-20210227","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","article-title":"The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells","volume":"128","author":"Riddell","year":"1990","journal-title":"J Immunol Methods"},{"key":"R52-2-20210227","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jim.2003.10.017","article-title":"The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo","volume":"285","author":"Hermans","year":"2004","journal-title":"J Immunol Methods"},{"key":"R53-2-20210227","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. [see comment]","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nature Med"},{"key":"R54-2-20210227","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2141.2005.05456.x","article-title":"Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells","volume":"129","author":"Cheadle","year":"2005","journal-title":"Br J Haematol"},{"key":"R55-2-20210227","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.cji.0000175492.28723.d6","article-title":"Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors","volume":"29","author":"Rossig","year":"2006","journal-title":"J Immunother"},{"key":"R57-2-20210227","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"R58-2-20210227","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"R59-2-20210227","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.4049\/jimmunol.168.10.4897","article-title":"4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function","volume":"168","author":"Wen","year":"2002","journal-title":"J Immunol"},{"key":"R60-2-20210227","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1073\/pnas.0306567101","article-title":"Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses","volume":"101","author":"Bukczynski","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R61-2-20210227","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2004-06-2482","article-title":"Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy","volume":"105","author":"Powell","year":"2005","journal-title":"Blood"},{"key":"R62-2-20210227","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. [see comment]","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"R63-2-20210227","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4049\/jimmunol.157.1.29","article-title":"Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function","volume":"157","author":"Kariv","year":"1996","journal-title":"J Immunol"},{"key":"R64-2-20210227","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1084\/jem.177.3.845","article-title":"Functional expression of B7\/BB1 on activated T lymphocytes","volume":"177","author":"Azuma","year":"1993","journal-title":"J Exp Med"},{"key":"R65-2-20210227","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2007-01-068932","article-title":"Cellular immune therapy for chronic lymphocytic leukemia","volume":"110","author":"Kater","year":"2007","journal-title":"Blood"},{"key":"R66-2-20210227","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.1993.tb00165.x","article-title":"Severe immunodeficiency in patients treated with fludarabine monophosphate","volume":"50","author":"Wijermans","year":"1993","journal-title":"Eur J Haematol"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0b013e3181ac6138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T01:26:05Z","timestamp":1685064365000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-200909000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e3181ac6138","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}